drugset / Trial / NCT01583530
Study of Belimumab Administered Subcutaneously to Healthy Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to measure the amount of belimumab in the blood when given as an injection under the skin (subcutaneously; SC) and to evaluate the safety and tolerability of multiple injections under the skin in healthy subjects.
Timeline
- Start
- 2011-02
- Primary completion
- 2011-09
- Completion
- 2011-09
Publications
- Gupta SV, Fanget MC, MacLauchlin C, Clausen VA, Li J, Cloutier D, Shen L, Robbie GJ, Mogalian E. Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection. Drugs R D. 2021 Dec;21(4):455-465. doi: 10.1007/s40268-021-00369-w. Epub 2021 Nov 6.
- Zhou X, Lee TI, Zhu M, Ma P. Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus. Drugs R D. 2021 Dec;21(4):407-417. doi: 10.1007/s40268-021-00363-2. Epub 2021 Oct 9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Belimumab | Monoclonal antibody | 200 mg | Intravenous |
| Comparator | Belimumab | Monoclonal antibody | 240 mg | Intravenous |
Indications
No indication recorded.